

NCIC CLINICAL TRIALS GROUP

**INVESTIGATIONAL NEW DRUG COMMITTEE**

DISEASE SITE COMMITTEE MEETING  
OPEN AGENDA

Delta Chelsea Hotel, Toronto, Ontario  
Friday, April 16, 2004 - 1:30 p.m. - 4:30 p.m.  
Room: Mountbatten Salon A

Chair: Gerald Batist

---

1:30 p.m. Welcome

**TRIAL REPORTS**

IND.141	Phase I	BAY 43-9006 AML or MDS	M Crump
IND.144	Phase I	LY293111 + irinotecan phase I	M Moore
IND.145	Phase II	ZD6474 myeloma	M Kovacs
IND.147	Phase I	OSI7836	G Goss
IND.148	Phase II	OSI774 Endometrium	A Fyles
IND.149	Phase II	OSI774 + carboplatin Ovary	H Hirte
IND.157	Phase I/II	OSI-774 + cisplatin head and neck	L Siu
IND.150	Phase II	PS-341 Mantle Cell Lymphoma	A Belch
IND.152	Phase II	PS-341 Waldenstrom's	C Chen
IND.153	Phase I	OGX-011	K Chi
IND.154	Phase I	OGX-011 + docetaxel	K Chi
IND.155	Phase I	Perifosine sarcoma	M Knowling
IND.156	Phase II	Perifosine melanoma	S Ernst
IND.160	Phase II	CCI-779 endometrium	A Oza
IND.161	Phase II	Triapine Renal Cell	J Knox

2:45 p.m. **BREAK**

3:15 p.m. **SPEAKER**  
New Agents at NCI US

K Kobayashi

3:45 p.m. **Discussion**

3:55 p.m. **UPDATES ON NEW PLANNED STUDIES/AGENTS** E Eisenhauer  
ALVAC melanoma vaccine: Phase I and randomized phase II trials (IND.158, IND.159)  
RAD001C: breast and glioma studies (IND.162, IND.163)  
OGX-011 + docetaxel breast and prostate (IND.164, IND.165)  
AEG35156 + docetaxel phase I (IND.166)  
BAY 43-9006: prostate (IND.167)  
SB 715992: melanoma and hepatocellular (IND.168, IND.169)  
GW572016 phase I/II glioma (IND.170)

4:15 p.m. **Report from Closed IND meeting and IND executive**

G Batist

4:30 p.m. **Adjourn**